Comparative Pharmacology
Head-to-head clinical analysis: ESKALITH CR versus LITHONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESKALITH CR versus LITHONATE.
ESKALITH CR vs LITHONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmitter activity, inhibits inositol monophosphatase, affects G-protein signaling, and alters gene expression for neuroprotective effects.
Lithium modulates neurotransmitter activity in the central nervous system, including inhibition of inositol monophosphatase, leading to reduced phosphoinositide signaling; alters G-protein coupled receptor signaling; and inhibits glycogen synthase kinase-3 (GSK-3). It also affects ion transport, including sodium and potassium, and stabilizes neuronal excitability.
Lithium carbonate extended-release (Eskalith CR) is administered orally. Typical adult starting dose: 300 mg 2-3 times daily. Maintenance dose: 900-1200 mg/day in 2-3 divided doses. Dose adjustments guided by serum lithium levels (target 0.6-1.2 mEq/L). Maximum dose: 2400 mg/day.
300-600 mg orally 2-3 times daily for acute mania; 600-1200 mg/day in divided doses for maintenance. Titrate to serum lithium level 0.8-1.2 mEq/L (acute) or 0.6-1.2 mEq/L (maintenance).
None Documented
None Documented
Terminal half-life: 18–24 hours (single dose); 24–36 hours (steady state). Extended due to slow tissue redistribution and age-related decreased GFR.
Terminal elimination half-life 18-36 hours in young adults, up to 48-72 hours in elderly or with renal impairment; steady state reached in 5-7 days.
Renal: >95% unchanged. Biliary/fecal: negligible (<1%).
Primarily renal excretion (>95% as unchanged lithium); less than 5% excreted in feces via bile.
Category C
Category C
Mood Stabilizer
Mood Stabilizer